{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T21:49:35Z","timestamp":1753739375376,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00467-023-05917-x","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T11:04:34Z","timestamp":1678791874000},"page":"2643-2648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-1157","authenticated-orcid":false,"given":"Hala","family":"Wannous","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"unstructured":"Alon US, Srivastava T (2017) Urolithiasis in children. In: Kher KK, Schnaper HW, Greenbaum LA (eds) Clinical Pediatric Nephrology, 3rd edn. Boca Raton, pp 1014\u20131015","key":"5917_CR1"},{"key":"5917_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1053\/j.ajkd.2021.07.018","volume":"79","author":"N Demoulin","year":"2022","unstructured":"Demoulin N, Aydin S, Gillion V, Morelle J, Jadoul M (2022) Pathophysiology and management of hyperoxaluria and oxalate nephropathy: a review. Am J Kidney Dis 79:717\u2013727. https:\/\/doi.org\/10.1053\/j.ajkd.2021.07.018","journal-title":"Am J Kidney Dis"},{"key":"5917_CR3","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.bbamcr.2006.08.021","volume":"1763","author":"CJ Danpure","year":"2006","unstructured":"Danpure CJ (2006) Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim Biophys Acta 1763:1776\u20131784","journal-title":"Biochim Biophys Acta"},{"key":"5917_CR4","doi-asserted-by":"publisher","first-page":"864580","DOI":"10.4061\/2011\/864580","volume":"2011","author":"J Harambat","year":"2011","unstructured":"Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P (2011) Primary hyperoxaluria. Int J Nephrol 2011:864580. https:\/\/doi.org\/10.4061\/2011\/864580","journal-title":"J Nephrol"},{"unstructured":"Milliner DS, Harris PC, Sas DJ, Cogal AG, Lieske JC (2002) Primary Hyperoxaluria Type 1. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A (eds). GeneReviews\u00ae [Internet]. University of Washington, Seattle, Seattle, 1993\u20132022","key":"5917_CR5"},{"key":"5917_CR6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/14728214.2018.1552940","volume":"23","author":"A Weigert","year":"2018","unstructured":"Weigert A, Martin-Higueras C, Hoppe B (2018) Novel therapeutic approaches in primary hyperoxaluria. Expert Opin Emerg Drugs 23:349\u2013357. https:\/\/doi.org\/10.1080\/14728214.2018.1552940","journal-title":"Expert Opin Emerg Drugs"},{"key":"5917_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.kint.2019.08.018","volume":"96","author":"SF Garrelfs","year":"2019","unstructured":"Garrelfs SF, Rumsby G, Peters-Sengers H, Erger F, Groothoff JW, Beck BB, Oosterveld MJS, Pelle A, Neuhaus T, Adams B, Cochat P, Salido E, Lipkin GW, Hoppe B, Hulton SA, OxalEurope Consortium (2019) Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. Kidney Int 96:1389\u20131399. https:\/\/doi.org\/10.1016\/j.kint.2019.08.018","journal-title":"Kidney Int"},{"key":"5917_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.kint.2021.03.031","volume":"100","author":"C Martin-Higueras","year":"2021","unstructured":"Martin-Higueras C, Garrelfs SF, Groothoff JW, Jacob DE, Moochhala SH, Bacchetta J, Acquaviva C, Zaniew M, Sikora P, Beck BB, Hoppe B (2021) A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. Kidney Int 100:621\u2013635. https:\/\/doi.org\/10.1016\/j.kint.2021.03.031","journal-title":"Kidney Int"},{"key":"5917_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8:467\u2013475. https:\/\/doi.org\/10.1038\/nrneph.2012.113","journal-title":"Nat Rev Nephrol"},{"key":"5917_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-022-01735-x","volume":"82","author":"B Hoppe","year":"2022","unstructured":"Hoppe B, Martin-Higueras C (2022) Improving Treatment Options for Primary Hyperoxaluria. Drugs 82:1077\u20131094. https:\/\/doi.org\/10.1007\/s40265-022-01735-x","journal-title":"Drugs"},{"key":"5917_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat P, Rumsby G (2013) Primary hyperoxaluria. N Engl J Med 369:649\u2013658. https:\/\/doi.org\/10.1056\/NEJMra1301564","journal-title":"N Engl J Med"},{"key":"5917_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1517\/13543784.2013.741587","volume":"22","author":"BB Beck","year":"2013","unstructured":"Beck BB, Hoyer-Kuhn H, G\u00f6bel H, Habbig S, Hoppe B (2013) Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert Opin Investig Drugs 22:117\u2013129. https:\/\/doi.org\/10.1517\/13543784.2013.741587","journal-title":"Expert Opin Investig Drugs"},{"key":"5917_CR13","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1016\/j.ekir.2020.09.022","volume":"5","author":"A Devresse","year":"2020","unstructured":"Devresse A, Cochat P, Godefroid N, Kanaan N (2020) Transplantation for primary hyperoxaluria type 1: designing new strategies in the era of promising therapeutic perspectives. Kidney Int Rep 5:2136\u20132145. https:\/\/doi.org\/10.1016\/j.ekir.2020.09.022","journal-title":"Kidney Int Rep"},{"key":"5917_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ekir.2021.11.006","volume":"7","author":"EL Metry","year":"2021","unstructured":"Metry EL, Garrelfs SF, Peters-Sengers H, Hulton SA, Acquaviva C, Bacchetta J, Beck BB, Collard L, Desch\u00eanes G, Franssen C, Kemper MJ, Lipkin GW, Mandrile G, Mohebbi N, Moochhala SH, Oosterveld MJS, Prikhodina L, Hoppe B, Cochat P, Groothoff JW, OxalEurope Consortium (2021) Long-term transplantation outcomes in patients with primary hyperoxaluria type 1 included in the European Hyperoxaluria Consortium (OxalEurope) registry. Kidney Int Rep 7:210\u2013220. https:\/\/doi.org\/10.1016\/j.ekir.2021.11.006","journal-title":"Kidney Int Rep"},{"key":"5917_CR15","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O\u2019Riordan WD, Cochat P, Desch\u00eanes G, Shasha-Lavsky H, Saland JM, van\u2019t Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators\u00a0(2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216\u20131226. https:\/\/doi.org\/10.1056\/NEJMoa2021712","journal-title":"N Engl J Med"},{"key":"5917_CR16","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","volume":"101","author":"B Hoppe","year":"2022","unstructured":"Hoppe B, Koch A, Cochat P, Garrelfs SF, Baum MA, Groothoff JW, Lipkin G, Coenen M, Schalk G, Amrite A, McDougall D, Barrios K, Langman CB (2022) Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int 101:626\u2013634. https:\/\/doi.org\/10.1016\/j.kint.2021.08.015","journal-title":"Kidney Int"},{"key":"5917_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","volume":"81","author":"LJ Scott","year":"2021","unstructured":"Scott LJ, Keam SJ (2021) Lumasiran: first approval. Drugs 81:277\u2013282. https:\/\/doi.org\/10.1007\/s40265-020-01463-0","journal-title":"Drugs"},{"key":"5917_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-021-00543-4","volume":"19","author":"K Shee","year":"2022","unstructured":"Shee K, Stoller ML (2022) Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol 19:137\u2013146. https:\/\/doi.org\/10.1038\/s41585-021-00543-4","journal-title":"Nat Rev Urol"},{"key":"5917_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4103\/1319-2442.225202","volume":"29","author":"NR Rhuma","year":"2018","unstructured":"Rhuma NR, Fituri OA, Sabei LT (2018) Mutational analysis of AGXT gene in Libyan children with primary hyperoxaluria type 1 at Tripoli Children Hospital. Saudi J Kidney Dis Transpl 29:30\u201338. https:\/\/doi.org\/10.4103\/1319-2442.225202","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"5917_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.gene.2013.06.023","volume":"527","author":"M Nagara","year":"2013","unstructured":"Nagara M, Tiar A, Ben Halim N, Ben Rhouma F, Messaoud O, Bouyacoub Y, Kefi R, Hassayoun S, Zouari N, Ben Ammar MS, Abdelhak S, Chemli J (2013) Mutation spectrum of primary hyperoxaluria type 1 in Tunisia: implication for diagnosis in North Africa. Gene 527:316\u2013320. https:\/\/doi.org\/10.1016\/j.gene.2013.06.023","journal-title":"Gene"},{"key":"5917_CR21","doi-asserted-by":"publisher","first-page":"615183","DOI":"10.3389\/fped.2021.615183","volume":"9","author":"A Guillaume","year":"2021","unstructured":"Guillaume A, Chiodini B, Adams B, Dahan K, Desch\u00eanes G, Ismaili K (2021) The struggling odyssey of infantile primary hyperoxaluria. Front Pediatr 9:615183. https:\/\/doi.org\/10.3389\/fped.2021.615183","journal-title":"Front Pediatr"},{"key":"5917_CR22","doi-asserted-by":"publisher","first-page":"15886","DOI":"10.1038\/s41598-022-17980-9","volume":"12","author":"NA Soliman","year":"2022","unstructured":"Soliman NA, Elmonem MA, Abdelrahman SM, Nabhan MM, Fahmy YA, Cogal A, Harris PC, Milliner DS (2022) Clinical and molecular characterization of primary hyperoxaluria in Egypt. Sci Rep 12:15886. https:\/\/doi.org\/10.1038\/s41598-022-17980-9","journal-title":"Sci Rep"},{"key":"5917_CR23","doi-asserted-by":"publisher","first-page":"634175","DOI":"10.1155\/2015\/634175","volume":"2015","author":"MS Al Riyami","year":"2015","unstructured":"Al Riyami MS, Al Ghaithi B, Al Hashmi N, Al Kalbani N (2015) Primary hyperoxaluria type 1 in 18 children: genotyping and outcome. Int J Nephrol 2015:634175. https:\/\/doi.org\/10.1155\/2015\/634175","journal-title":"Int J Nephrol"},{"key":"5917_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/1744-9987.13666","volume":"26","author":"FI Fadel","year":"2022","unstructured":"Fadel FI, Kotb MA, Abdel Mawla MA, Hasanin RM, Salem AM, Fathallah MG, Amr KS, Ahmed HA, Salah DM (2022) Primary hyperoxaluria type 1 in children: clinical classification, renal replacement therapy, and outcome in a single centre experience. Ther Apher Dial 26:162\u2013170. https:\/\/doi.org\/10.1111\/1744-9987.13666","journal-title":"Ther Apher Dial"},{"key":"5917_CR25","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone Consortium (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559\u20132570. https:\/\/doi.org\/10.1681\/ASN.2014070698","journal-title":"J Am Soc Nephrol"},{"key":"5917_CR26","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2215\/CJN.07430711","volume":"7","author":"J Harambat","year":"2012","unstructured":"Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, European Society for Pediatric Nephrology\/European Renal Association-European Dialysis and Transplant Association (ESPN\/ERA-EDTA) Registry (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458\u2013465. https:\/\/doi.org\/10.2215\/CJN.07430711","journal-title":"Clin J Am Soc Nephrol"},{"key":"5917_CR27","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","volume":"10","author":"EJ Bergstralh","year":"2010","unstructured":"Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, Milliner DS; IPHR Investigators (2010) Transplantation outcomes in primary hyperoxaluria. Am J Transplant 10:2493\u20132501. https:\/\/doi.org\/10.1111\/j.1600-6143.2010.03271.x","journal-title":"Am J Transplant"},{"key":"5917_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/089686089401400117","volume":"14","author":"TE Bunchman","year":"1994","unstructured":"Bunchman TE, Swartz RD (1994) Oxalate removal in type I hyperoxaluria or acquired oxalosis using HD and equilibration PD. Perit Dial Int 14:81\u201384","journal-title":"Perit Dial Int"},{"key":"5917_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/sj.ki.5001806","volume":"70","author":"F Illies","year":"2006","unstructured":"Illies F, Bonzel KE, Wingen AM, Latta K, Hoyer PF (2006) Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1. Kidney Int 70:1642\u20131648. https:\/\/doi.org\/10.1038\/sj.ki.5001806","journal-title":"Kidney Int"},{"key":"5917_CR30","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s004670050145","volume":"10","author":"B Hoppe","year":"1996","unstructured":"Hoppe B, Graf D, Offner G, Latta K, Byrd DJ, Michalk D, Brodehl J (1996) Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr Nephrol 10:488\u2013492. https:\/\/doi.org\/10.1007\/s004670050145","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-05917-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-05917-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T07:15:37Z","timestamp":1690874137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-05917-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["5917"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-05917-x","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"type":"print","value":"0931-041X"},{"type":"electronic","value":"1432-198X"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The author has no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}